|
July 18, 2022 |
Q&A with ARUP’s Michael T. Pyne: Developing an NGS Assay for HIV-1 Antiretroviral Drug Resistance Scientist Michael T. Pyne shares ARUP’s challenges and process of developing a next generation sequencing (NGS) test for HIV-1 antiretroviral drug resistance. |
ARUP Consult®, a free source of laboratory testing information for clinicians, released several new and updated resources in June. |
July 6, 2022 | ARUP Consult, a free source of expert guidance in laboratory testing, has released new and updated resources on testing for immunobullous diseases, diabetes mellitus, and prostate cancer. |
|
June 23, 2022 |
ARUP Launches New Interactive Tool to Compare and Choose Immunobullous Disease Tests ARUP offers several antibody panels to test for immunobullous diseases, which are difficult to diagnose. The Immunobullous Disease Testing Comparison tool allows users to quickly compare test options. |
|
June 15, 2022 | ARUP experts say that the VALID Act, which would require FDA approval of all lab-developed tests, would add administrative and financial burdens to an already safe and effective validation process. |
|
June 13, 2022 | ARUP Laboratories invites medical professionals to participate in a free webinar that will feature creative solutions to address the current laboratory and hospital staffing crisis. |
|
June 10, 2022 |
ARUP’s Operations Director to Share Lessons From COVID-19 During SmartBrief Webinar ARUP’s Dan Anderson will participate in a SmartBrief webinar on June 16 to share lessons learned from COVID-19 in an effort to help laboratories prepare for future pandemics. |

























